RxDoctor Payments Data

Peter Futrell, MD

Neurology · Cumming, GANPI 1912990391

Payments from drug & device makers

$34,076in general payments, 2019–2025

Across 1,870 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • UCB, Inc.$2K
  • Biogen$2K
  • Pfizer$1K
  • Acadia Pharmaceuticals Inc$1K
  • Eisai Inc.$1K
  • plus $21K from 54 others

What the payments were for

  • Consulting fees$1500%
  • Speaking & faculty fees$600%
  • Food & beverage$33,79499%
  • Education$720%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)295$4,055
UCB, Inc.95$1,968
Biogen94$1,842
Pfizer107$1,486
Acadia Pharmaceuticals Inc78$1,395
Eisai Inc.73$1,346
AstraZeneca(2 entities)57$1,247
Lundbeck LLC49$1,211
Novartis74$1,177
Neurocrine Biosciences, Inc.58$1,165
Lilly USA, LLC53$1,028
EMD Serono, Inc.59$988
Biohaven Pharmaceuticals, Inc.46$911
MDD US Operations, LLC29$894
Amgen(2 entities)36$892
Sunovion Pharmaceuticals Inc.61$856
Avanir Pharmaceuticals, Inc.43$779
Teva Pharmaceuticals USA, Inc.45$655
Jazz Pharmaceuticals Inc.30$632
Supernus Pharmaceuticals, Inc.54$607
Otsuka America Pharmaceutical, Inc.27$605
Sanofi27$513
Catalyst Pharmaceuticals, Inc.18$504
Biohaven Pharmaceutical Holding Company Ltd.29$427
Argenx US, Inc.16$417
Kyowa Kirin, Inc.21$374
Adamas Pharmaceuticals, Inc.23$369
Amneal Pharmaceuticals LLC21$346
Sumitomo Pharma America, Inc.13$321
CSL Behring13$301
Johnson & Johnson(2 entities)10$278
Harmony Biosciences LLC14$269
Impel Pharmaceuticals Inc.14$255
Bristol Myers Squibb8$255
Bausch Health US, LLC11$209
Banner Life Sciences, LLC5$207
Ipsen Biopharmaceuticals, Inc10$207
Axsome Therapeutics, Inc.7$196
Mallinckrodt Hospital Products Inc.9$194
Upsher-smith Laboratories LLC10$176
Neurelis, Inc.7$173
Grifols USA, LLC8$164
Currax Pharmaceuticals LLC10$137
Azurity Pharmaceuticals, Inc.7$133
Acorda Therapeutics, Inc7$128
Avion Pharmaceuticals6$108
GE HealthCare6$104
Scilex Pharmaceuticals Inc.5$103
Boston Scientific5$96
SK Life Science, Inc.5$96
Genentech USA, Inc.4$96
Cycle Pharmaceuticals Inc3$92
Forte Bio-pharma LLC4$88
Aprecia Pharmaceuticals, LLC4$82
Takeda Pharmaceuticals U.S.A., Inc.3$74
Vanda Pharmaceuticals Inc.2$71
Vertical Pharmaceuticals, LLC4$68
Corium, LLC3$63
Mallinckrodt Enterprises LLC3$59
Arbor Pharmaceuticals, Inc.2$45

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,076 in reported general payments places this provider in the 85th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$620,611
Medicare patients
624
Services billed
83,756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate12$230,626
AustedoDeutetrabenazine12$90,694
NuplazidPimavanserin Tartrate12$69,770
Nurtec OdtRimegepant Sulfate44$42,262
QuliptaAtogepant21$25,784
Emgality PenGalcanezumab-Gnlm28$23,575
DilantinPhenytoin Sodium Extended64$9,992
NamzaricMemantine Hcl/Donepezil Hcl14$7,625
Levetiracetam235$6,507
Gabapentin235$6,400
EliquisApixaban11$6,205
DepakoteDivalproex Sodium18$5,798
Carbidopa-LevodopaCarbidopa/Levodopa199$4,438
Pyridostigmine Bromide45$4,132
Primidone197$3,989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$655$90,69412 claims
Acadia Pharmaceuticals IncNuplazid$1,395$69,77012 claims
PfizerNurtec Odt, Dilantin, Eliquis$1,486$58,460119 claims
AbbVieQulipta, Namzaric$4,055$33,40935 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$346$6,69368 claims
Upsher-smith Laboratories LLCTopiramate$176$1,02390 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 506 neurology providers in Georgia.

Other neurology in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →